Hence, controlled expression of Mg29 in the failing heart, such as with viral gene therapy approaches, may offer a novel way to correct the reduction in coordinated coupling between the sarcolemma and SR that occurs in heart failure, similar to the strategy recently proposed for Jph230. The gene discussed is SYPL2; the disease is heart failure.